MedTrace Logo

Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007

NCT05079828 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-12-10

No results posted yet for this study

Summary

The aim of this study is to provide robust data on the head-to-head comparison of the two ligands of the prostate specific membrane antigen (PSMA) available in Switzerland for positron emission tomography (PET)-imaging, i.e. 68Ga-PSMA-11 und 18F-PSMA-1007.

Conditions

Interventions

DIAGNOSTIC_TEST

18F-PSMA-1007

PET/CT scan using 18F-PSMA-1007

DIAGNOSTIC_TEST

68Ga-PSMA-11

PET/CT scan using 68Ga-PSMA-11

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Axel Rominger, MD · Inselspital

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-07
Primary Completion
2024-05-01
Completion
2024-10-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05079828 on ClinicalTrials.gov